Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CyPep-1 · 1 trial · 3 indications
Number of CyPep-1 related TEAEs per grading.
Number of DLTs
| Arm | Type | Description |
|---|---|---|
| Arm A: advanced or metastatic HNSCC | EXPERIMENTAL | The safety and tolerability of CyPep-1 in combination with pembrolizumab will be evaluated in a cohort of 30 subjects in total with advanced or metastatic HNSCC. CyPep-1 will be administered every 2 weeks (Q2W) and pembrolizumab will be administered following a Q6W schedule as per standard of care (SoC). |
| Arm B: advanced or metastatic melanoma | EXPERIMENTAL | The safety and tolerability of CyPep-1 in combination with pembrolizumab will be evaluated in a cohort of 30 subjects in total with advanced or metastatic melanoma. CyPep-1 will be administered every 2 weeks (Q2W) and pembrolizumab will be administered following a Q6W schedule as per standard of care (SoC). |
| Arm C: advanced or metastatic TNBC | EXPERIMENTAL | The safety and tolerability of CyPep-1 in combination with pembrolizumab will be evaluated in a cohort of 30 subjects in total with advanced or metastatic TNBC. CyPep-1 will be administered every 2 weeks (Q2W) and pembrolizumab will be administered following a Q6W schedule as per standard of care (SoC). |
| Name | Type | Description |
|---|---|---|
| CyPep-1 | DRUG | Intratumoral injection |
| Pembrolizumab 25 MG/ML [KEYTRUDA®] | DRUG | IV infusion |
Inclusion Criteria: General Inclusion Criteria 1. Is 18 years of age or older on the day of signing informed consent; 2. Provides written informed consent and is able to comply with study procedures and assessments; 3. Has measurable disease as determined by the Response Evaluation Criteria in Sol...
CyPep-1 is an investigational small molecule being studied for the treatment of advanced head and neck squamous cell carcinoma. It is being evaluated in combination with pembrolizumab for advanced or metastatic cancers, including head and neck squamous cell carcinoma, breast cancer, and melanoma. CyPep-1 is currently in Phase 1 clinical development.
CyPep-1 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The drug is currently in Phase 1 clinical development for the treatment of advanced head and neck squamous cell carcinoma.
CyPep-1 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 study evaluating CyPep-1 in combination with pembrolizumab for advanced or metastatic cancers has been completed.
CyPep-1 has been studied in one clinical trial, identified as NCT05383170. This Phase 1 study evaluated the safety and efficacy of CyPep-1 in combination with pembrolizumab for the treatment of advanced or metastatic cancers, including head and neck squamous cell carcinoma, breast cancer, and melanoma. The trial enrolled 6 participants and has been completed.
No, CyPep-1 is not the same as pembrolizumab. CyPep-1 is an investigational small molecule being developed by Merck & Company, Inc. Pembrolizumab is a separate drug that was used in combination with CyPep-1 in a clinical trial for the treatment of advanced or metastatic cancers.